CUMULATIVE INDEX 1994

Volume 23

March	GASTROINTESTINAL BLEEDING II, pages 1–188
June	POSTSURGICAL SYNDROMES, pages 189–428
September	VIRAL HEPATITIS, pages 429–620
December	PEDIATRIC GASTROENTEROLOGY, PART I, pages 621–788

Note: Page numbers of issue and article titles are in **boldface** type.

Absorption, nutrient, in short bowel syndrome, strategies for, 405–408
of caloric foods, disorders of, after gastric surgery, 228–241
Acarbose, for dumping syndrome, 267
Accommodation response, gastric, 200–201
Achalasia, esophageal, dysphagia in, 220
Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection.*
Acrodermatitis, papular, in hepatitis B, 757
Actin, antibodies to, in autoimmune hepatitis, 548
Acyclovir, in hepatitis B, 584
in hepatitis C, 610
Adenine arabinoside, in hepatitis B, 584
Adenocarcinoma, small intestinal, bleeding from, 72
Adenomatous polyposis syndromes, bleeding in, 111–112
Adenovirus infection, hepatitis in, in pediatric patients, 764
Afferent loop syndromes, postoperative, evaluation of, 224–225
Aganglionosis coli, bleeding in, 99–100
AIDS. See *Human immunodeficiency virus infection.*
Alanine aminotransferase, in hepatitis B, 588
in hepatitis E, 539–540
Alcoholic liver disease, hepatocellular carcinoma and, 573
Alkaline Bernstein test, in alkaline reflux gastritis, 288–289
Alkaline reflux gastritis, postoperative, **281–294**
clinical presentation of, 286–287
diagnosis of, 191, 287–289
pathophysiology of, 282–286
treatment of, 289–291
Allergy, to cow's-milk protein, bleeding in, 100–101
Alpha-fetoprotein, measurement of, in hepatocellular carcinoma screening, 574–575
Aminoaciduria, with hereditary pancreatitis, 747
Amniotic fluid, ingestion of, 658–659
Amoxicillin, in peptic ulcer disease, in pediatric patients, 719–720
Ampicillin, in peptic ulcer disease, in pediatric patients, 108, 719
Amylase, in hereditary pancreatitis, 745
Amyloidosis, bleeding in, 35
Anemia, after bariatric surgery, 366
after gastric surgery, 245–249
Angelchik prosthesis insertion, results of, 377–378
Angina pectoris, vs. heartburn, 220
Angiodysplasia, colonic, 2–10
small intestinal, 68–71, 75–76
Angiography. See also *Visceral arteriography.*
in colonic varices, 24
in diverticulosis, 14–15, 17–18
in small intestinal bleeding, 78–80, 85
in vascular ectasia, 8–9, 69–70
Anorectal manometry, in defecation disorders, in pediatric patients, 630
Antacids, in alkaline reflux gastritis, 289
in peptic ulcer disease, in pediatric patients, 716
Antibiotics, *Clostridium difficile* infection related to, in pediatric patients, 639–640

Antibiotics *(Continued)*
in peptic ulcer disease, in pediatric patients, 718–720
Antibodies, in autoimmune hepatitis, 553–554, 556, 560–561
cryptogenic, 551
type 1, 548–549
type 2, 549–550
type 3, 551
in viral hepatitis. See also under specific virus.
determination of, 459
Antibody capture test, in hepatitis diagnosis, 459
Antigens, of hepatitis viruses. See also under specific virus.
determination of, 459–460
Antinuclear antibodies, in autoimmune hepatitis, 548, 556
Antireflux surgery, **371–389**
complications of. See also *Roux stasis (limb) syndrome.*
dysphagia, 219–220, 379–382
gastric functional abnormalities, 382–384
recurrent hernia, 384–385
recurrent reflux, 378–379
reoperation for, 385–386
patient selection for, 371–372
repeated, 385–386
results of, 371–372
Angelchik prosthesis insertion, 377–378
Belsey Mark IV procedure, 372–373
Hill operation, 373–374
Nissen fundoplication, 219, 374–377
video-assisted, 386–387
Antiviral agents, in hepatitis B, historical view of, 583–584
Antral G-cell hyperfunction, recurrent peptic ulcer and, 300–301
Antrectomy, gastric emptying after, 205, 314, 331
Antroduodenal motility, in pediatric patients, development of, 661–665
feeding effects on, 665
preterm infants, 665–666
Anus, stenosis of, in pediatric patients, 627
Aortic stenosis, angiodysplasia in, 70–71
Aortoenteric fistula, bleeding in, 167–168, 170–172
Aphthous ulcers, in small intestine graft rejection, 732–733
Apt-Downey test, in bleeding, in pediatric patients, 94
Arterial embolism, mesenteric, 28
Arterial thrombosis, mesenteric, 28
Arteriography. See *Angiography.*
Arteriovenous malformation, arteriography of, 136
colonic, 2–10
small intestinal, 76
Arthritis-dermatitis syndrome, after bariatric surgery, 356–357
Asian Americans, hepatitis B in. See under *Hepatitis B.*
Atony, gastric, in Roux syndrome. See *Roux stasis (limb) syndrome.*
Autoimmune hepatitis, **547–566**
cryptogenic, 551
diagnosis of, 555–558
exacerbation of, interferon in, 589–590
false viral markers in, 559–560
hepatitis A in, 553
hepatitis B in, 552–553, 555, 557–558, 560
hepatitis C in, 434, 549–561
histology of, 538
HIV infection in, 553
in pediatric patients, 764
treatment of, 558–561
type 1 (classic, lupoid), 548–549
type 2, 549–550
type 3, 551
viral origin of, 552–555
vs. hepatitis C, 557
vs. viral hepatitis, 560–561
with high-titer autoantibodies, 561
with low-titer autoantibodies, 560
Azathioprine, in small intestine transplantation, 735
Azotorrhea, after gastric surgery, 229

Bacterial overgrowth, after gastric surgery, 253–254
in short bowel syndrome, 410
Balloon dilation, of esophagus, after antireflux surgery, 381
Banding, gastric, in morbid obesity, 349
Bariatric surgery, **345–369**
complications of, 350–367
abdominal pain, 364
anatomic effects, 353
arthritis-dermatitis syndrome, 356–357
cholelithiasis, 353–354
diarrhea, 355
due to knowledge deficits, 352
gastroesophageal reflux, 363
in gastric restrictive operations, 359–367
in malabsorptive operations, 354–358
inadequate weight loss, 366–367
intestinal, 357–358
liver dysfunction, 358
metabolic, 355–356
neurologic, 366
nutritional, 365–366
peptic ulcer disease, 362–363
perioperative, 350–351

physiologic, 353
prosthesis erosion, 364–365
psychosocial influences on, 352
urinary stones, 356
vomiting, 359–362
weight loss, 353
stoma dilation after, 361–362
techniques for, 346–350
weight loss after, 244–245
Barium enema, in defecation disorders, in pediatric patients, 629
in occult bleeding, 62–63
in solitary rectal ulcer syndrome, 23
Barium studies, in bleeding, 124–125
in dysphagia, 216–217
in peptic ulcer disease, in pediatric patients, 711–712
Behavioral modification, for defecation disorders, in pediatric patients, 633–634
Belch, inability to, after antireflux surgery, 382–384
Belsey Mark IV procedure, results of, 372–373
Bernstein test, alkaline, in alkaline reflux gastritis, 288–289
Bethanechol, in postgastrectomy syndromes, 315–316, 338
Bile acids, in alkaline reflux gastritis, 285–286, 289–290
in vitamin E absorption, 694
Biliopancreatic bypass, in morbid obesity, 349–350
Billroth I procedure, complications of, dumping syndrome, 270
gastric emptying alterations, 239, 332
weight loss, 242–243
Billroth II procedure, complications of, alkaline reflux gastritis, 287
gastric emptying alterations, 331
loop syndromes, 224–225
pancreatic dysfunction, 236, 239
weight loss, 242–243
conversion to Billroth I anastomosis, in dumping syndrome, 270
Biofeedback training, for defecation disorders, in pediatric patients, 634
Biopsy, in peptic ulcer disease, in pediatric patients, 713
liver, in hepatitis B, 582–583
Bishop-Coop ileostomy, in small intestine transplantation, 731
Bismuth compounds, in peptic ulcer disease, in pediatric patients, 108, 719–720
Bleeding, colonic. See under *Colon*.
drug-induced, small intestinal, 74
esophageal, 58, 101–102
evaluation of. See also specific disorder.
small intestinal, 76–85
in angiodysplasia, colonic, 2–10
small intestinal, 68–71, 75–76
in congenital malformations, 95–98
in Dieulafoy lesion, 33–34
in diversion colitis, 27
in diverticulosis, colonic, **1–20**
small intestinal, 31–32, 74–75
in endometriosis, 41–43
in end-stage liver disease, 105
in gastroesophageal reflux, 101–102
in hemolytic-uremic syndrome, 104–105
in Henoch-Schönlein purpura, 34, 103–104
in hereditary disorders, 109–112
in Hirschsprung's-associated enterocolitis, 99–100
in infections. See *Infections*.
in inflammatory bowel disease, 108–109
in intestinal duplication, 95–96
in intussusception, 38–40, 102–103
in lymphoid nodular hyperplasia, 102
in marathon running, 40–41
in Meckel's diverticulum, 32–33, 73, 96–97
in mesenteric vascular insufficiency, 27–31
in necrotizing enterocolitis, 98–99
in pediatric patients, **93–122**
in congenital malformations, 95–98
in early-childhood disorders, 98–105
in hereditary disorders, 109–112
in later-childhood disorders, 106–109
in peptic ulcer disease, treatment of, 715–716
in spurious conditions, 94
in peptic ulcer disease, 58, 106–107, 152–153
recurrent, 297
in polyposis, 109–112
in portal colopathy, 24–25
in radiation-induced injury, 25–26, 74
in solitary rectal ulcer syndrome, 21–24
in spurious conditions, in pediatric patients, 94
in tumors, small intestinal, 71–72
in ulceration, in solitary rectal ulcer syndrome, 21–24
small intestinal, 36–38, 72–73
in varices. See *Varices*.
in vascular ectasia, **1–20**
colonic, 2–10
small intestinal, 68–71
in vascular lesions, small intestinal, 75–76
in vascular malformation, 97–98
arteriography of, 136
occult, 59
in vasculitis, 34–36
small intestinal, 74
in Zollinger-Ellison syndrome, small intestinal, 73

Bleeding *(Continued)*
jejunal. See *Jejunum.*
occult, **53–66**
radiology in. See *Radiology.*
reactivation of, for diagnostic studies, 131–132
small intestinal. See under *Small intestine.*
traumatic, arteriography in, 135
treatment of. See also specific disorder.
small intestinal, 86–88
unusual causes of, **21–52**
Bloating, after antireflux surgery, 382–384
Blood, viral transmission in, hepatitis B, 442–443
hepatitis C, 446–447, 449
hepatitis delta, 450
Bone disease, after gastric surgery, 249–253
Branched DNA amplification, in viral hepatitis diagnosis, 489–490
Breast-feeding, blood ingestion in, 94
milk protein intolerance in, 100
Breath tests, in peptic ulcer disease, in pediatric patients, 713–714
Bypass enteritis, after bariatric surgery, 357

Calcification, of pancreas, 745, 747
Calcium disorders, after gastric surgery, 251–252
Caliciviridae, hepatitis E virus as, 542
Cancer, gastric, surgery for, reflux after, 221–222
Carbohydrate malabsorption, after gastric surgery, 229, 231
Carcinoma, hepatocellular. See *Hepatocellular carcinoma.*
Cardiac events, after bariatric surgery, 351
Carotenoids. See *Vitamin A.*
Catheterization, selective, in bleeding therapy, vasopressin in, 139–143
Catheter-related disorders, in short bowel syndrome, 409
Cecum, bleeding in, 134
Chemiluminescence techniques, in viral hepatitis diagnosis, 486
Chemotherapy, hepatitis B reactivation in, 465
in hepatocellular carcinoma, 575
Chimerism, in small intestine transplantation, 739
Cholecystectomy, after bariatric surgery, 354
gastrointestinal pacing after, 399–400
Cholecystokinin, secretion of, after vagotomy, 210
Cholelithiasis, after bariatric surgery, 353–354
after gastrectomy, 209–210
after vagotomy, 209–210
in parenteral nutrition, 409
Cholera, in pediatric patients, 638–639, 643–645
Cholestasis, in pediatric patients, fat-soluble vitamins and, **673–705**
vitamin A, 674–682
vitamin D, 682–689
vitamin E, 691–702
vitamin K, 689–691
small intestine transplantation in, 730
Cholestyramine, in short bowel syndrome, 407
Chronic idiopathic intestinal pseudo-obstruction syndrome, in pediatric patients, 627
Churg-Strauss syndrome, bleeding in, 34
Cimetidine, in peptic ulcer disease, in pediatric patients, 107
Cirrhosis, after bariatric surgery, 358
epidemiology of, in Asian Americans, 529–530
in hepatitis C, 445–446
Cisapride, in gastric emptying, in pediatric patients, 661
in postgastrectomy syndromes, 316, 318–320, 338
Clarithromycin, in peptic ulcer disease, in pediatric patients, 719
Cloning, of viral hepatitis genes, 483–484
Clostridium difficile infection, in pediatric patients, 639–640
Clotting factors, measurement of, in vitamin K status evaluation, 690
Colectomy, in diverticulosis, 15
in vascular ectasia, 9–10, 18
Colitis, diversion, 27
fulminant, in pediatric patients, 109
hemorrhagic, enterohemorrhagic *Escherichia coli* in, 641–642
in cow's-milk protein intolerance, 100–101
ischemic, 30–31
ulcerative, in pediatric patients, 108–109
Colon, absorption in, in short bowel syndrome, 407–408
bleeding in, after diversion, 27
evaluation of, 16–18
in cow's-milk protein intolerance, 100–101
in Dieulafoy lesion, 33–34
in diverticulosis, **1–20**
in endometriosis, 41–43
in Gardner's syndrome, 111–112
in hemolytic-uremic syndrome, 104–105
in Hirschsprung's-associated enterocolitis, 99–100
in infections, 112

in inflammatory bowel disease, 108–109
in intestinal duplication, 95–96
in intussusception, 38–40, 102–103
in lymphoid nodular hyperplasia, 102
in marathon running, 40–41
in mesenteric vascular insufficiency, 27–31
in necrotizing enterocolitis, 98–99
in polyposis, 109–112
in portal colopathy, 24–25
in varices, 24–25, 137
in vascular ectasia, 2–10
in vascular malformation, 97–98
in vasculitis, 34–36
occult, **53–66**
radiologic management of. See *Radiology, in bleeding management.*
vasopressin therapy in, 139–143
interposition of, in small intestine resection, 413
manometry of, in pediatric patients, 631
motility of, development of, 666–667
obstruction, after bariatric surgery, 358
Colonic transit time, in defecation disorders, in pediatric patients, 630
Colonoscopy, in bleeding, 124–125
in diverticulosis, 14, 17
in portal colopathy, 25
in vascular ectasia, 7–8
occult, 63
Colorectal cancer, intussusception in, 39
occult bleeding in, 53
screening for, 59–62
testing for, 56
Computed tomography, in hereditary pancreatitis, 745
Congenital malformations, bleeding in, 95–98
Congo red test, in recurrent peptic ulcer, 303–305
Conjunctival impression cytology method, in vitamin A status evaluation, 681
Constipation, in pediatric patients, **621–636**
causes of, 625, 627
defecation physiology and, 622–623
definition, 621
diagnosis of, 628–631
incidence, 621
treatment of, 631–634
Corticosteroids, after small intestine transplantation, 731
in autoimmune hepatitis, 549
in hepatitis B, 593–594
in hepatitis C, 610
in small intestine transplantation, 735
prenatal, in fetal motility development, 666
Cowden's syndrome, bleeding in, 110
Cow's-milk protein intolerance, bleeding in, 100–101
Coxsackie A virus infection, hepatitis in, in pediatric patients, 764
Crohn's disease, bleeding in, 72–73
in pediatric patients, 108–109
Cronkhite-Canada syndrome, bleeding in, 110
CRST syndrome, bleeding in, small intestinal, 76
Cryoglobulinemia, bleeding in, 36
Cryptogenic hepatitis, 551
Cryptosporidium infection, in pediatric patients, 642–643
Culture, of *Helicobacter pylori*, in pediatric patients, 713
"Currant jelly stool," in intussusception, 102
Cyclospora cayetanensis infection, in pediatric patients, 643
Cytochrome mono-oxygenase, antibodies to, in autoimmune hepatitis, 550
Cytomegalovirus infection, hepatitis in, in pediatric patients, 764
in HIV infection, 518–519

Defecation, disorders of. See also *Constipation; Diarrhea; Encopresis.*
classification of, 624–628
clinical presentation of, 624–628
mechanisms for, development of, 666–667
physiology of, 622–623
Defecography, in pediatric patients, 630
Delta hepatitis. See *Hepatitis delta.*
Dermatitis, after bariatric surgery, 356–357
Diarrhea, after bariatric surgery, 355
after vagotomy, 272–275
in short bowel syndrome, management of, 406–408
infectious, in pediatric patients, **637–654**
Clostridium difficile in, 639–640
Cryptosporidium in, 642–643
Cyclospora cayetanensis in, 643
enterohemorrhagic *Escherichia coli* in, 641–642
enterotoxigenic *Escherichia coli* in, 647–648
epidemiology of, 637
rotavirus in, 645–647
Shigella in, 648–649
vaccines for, 643–649
Vibrio cholerae in, 638–639, 643–645
Dideoxyinosine, in hepatitis B, 584
Diet, diverticulosis and, 10, 13
for defecation disorders, in pediatric patients, 631–634
for diarrhea, after bariatric surgery, 355
for dumping syndrome, 265–266
occult blood testing and, 55

Dieulafoy lesion, 33–34
radiologic management, 174
Distal onlay-reversed ileal graft, in postvagotomy diarrhea, 275
Diversion, colitis, 27
Diverticula, arteriography of, 132–133
colonic, 10–18
anatomy of, 11–12
clinical features of, 14
epidemiology of, 12–13
evaluation of, 14–15
pathophysiology of, 13
treatment of, 15
jejunal, 74–75
Meckel's, 32–33, 73
in pediatric patients, 96–97
small intestinal, 31–32, 74–75
Domperidone, in postgastrectomy syndromes, 320, 338
Dot blot hybridization, in viral hepatitis diagnosis, 485–486
Dumping syndrome, **261–272**
after gastric surgery, 244
clinical features of, 261–262
diagnosis of, 265
early, 262–264
incidence of, 264
late, 264
pathophysiology of, 262–264
prevention of, 264–265
treatment of, medical, 265–269
pacing in, 396–398
surgical, 269–272
Duodenum, bleeding in, in vascular lesions, 75–76
motility of, in pediatric patients, development of, 661–665
feeding effects on, 665
preterm infants, 665–666
pacemaker of, 393
Duplication, intestinal, bleeding in, 95–96
Dysentery, bacillary, in pediatric patients, 648–649
Dysphagia, after antireflux surgery, 219–220, 379–382
Hill operation, 373–374
Nissen fundoplication, 219, 374
after gastrectomy, evaluation of, 216–220
after vagotomy, evaluation of, 217–219
in achalasia, 220

Eating disorders, after small intestine transplantation, 738–739
Ectasia, vascular. See *Vascular ectasia.*
Education, patient, on bariatric surgery, 352
Efferent loop syndromes, postoperative, evaluation of, 225
Electrolytes, loss of, in short bowel syndrome, 408
Electromyography, in defecation disorders, in pediatric patients, 631
ELISA. See *Enzyme-linked immunosorbent assay.*
Embolism, of mesenteric arteries, 28
Embolization, in bleeding therapy, 143, 146–147, 149–156
in Dieulafoy lesion, 174
in hemobilia, 170, 173
in portal hypertension, 162
in vascular ectasia, 9
Emptying, gastric. See *Gastric emptying.*
Encopresis, in pediatric patients, **621–636**
causes of, 624–625
defecation physiology and, 622–623
definition, 621–623
diagnosis of, 628–631
treatment of, 631–634
Endometriosis, gastrointestinal bleeding in, 41–43
Endoscopy. See also *Colonoscopy.*
in alkaline reflux gastritis, 288
in peptic ulcer disease, in pediatric patients, 712
in postoperative reflux, 222
in recurrent peptic ulcer, 298–299
of small intestine (enteroscopy), 80–84
in rejection monitoring, 732
therapeutic, in peptic ulcer disease, in pediatric patients, 715–716
Enema. See also *Barium enema.*
for defecation disorders, in pediatric patients, 634
Enteric nervous system, development of, 656–658
Enteritis, bypass, after bariatric surgery, 357
chronic ulcerative, 38
Enteroclysis, in bleeding evaluation, 76–78
Enterocolitis, Hirschsprung's-associated, 99–100
necrotizing, 98–99
radiation, 25–26
Enterohemorrhagic *Escherichia coli* infection, in pediatric patients, 641–642
Enteroscopy, 80–84
Enterotoxigenic *Escherichia coli* infection, in pediatric patients, 647–648
Enzyme-linked immunosorbent assay, in hepatitis diagnosis, 458–459
hepatitis A, 458–459
hepatitis C, 467–468
Eosinophilia, in cow's-milk protein intolerance, 100–101
Epstein-Barr virus infection, after small intestine transplantation, 737–738
hepatitis in, in pediatric patients, 763–764

Erythromycin, in gastric emptying, in pediatric patients, 661
in postgastrectomy syndromes, 320–322, 335, 338
Escherichia coli infection, hemolytic-uremic syndrome in, 105
in pediatric patients, enterohemorrhagic, 641–642
enterotoxigenic, 647–648
Esophageal varices, arteriography of, 138
in pediatric patients, 105
radiologic management of, 160, 162–163, 166–167
Esophagitis, occult bleeding in, 58
Esophagogastric junction reflux, after vagotomy, 197
Esophagogastroduodenoscopy, in bleeding evaluation, occult, 63
small intestinal, 81–83
in peptic ulcer disease, in pediatric patients, 712
Esophagus, achalasia of, dysphagia in, 220
bleeding in, in gastroesophageal reflux, 101–102
dilation of, after antireflux surgery, 381
luminal narrowing of, dysphagia in. See *Dysphagia*.
motility of, development of, 659
reflux in. See *Reflux, gastroesophageal*.
Essential mixed cryoglobulinemia, bleeding in, 36
Evacuation proctography, in pediatric patients, 630
Exercise, gastrointestinal bleeding in, 40–41

Factors, clotting, measurement of, in vitamin K status evaluation, 690
Familial adenomatous polyposis, bleeding in, 111
Familial juvenile polyposis, 110
Familial pancreatitis. See *Pancreatitis, hereditary*.
Famotidine, in peptic ulcer disease, in pediatric patients, 107
Fat, absorption of, in short bowel syndrome, 406
Fecal soiling, in pediatric patients. See *Encopresis*.
Fetus, gastrointestinal motility development in. See *Motility, in pediatric patients, development of*.
Fiber, dietary, for dumping syndrome, 266–267
Fistula, after Nissen fundoplication, 376
aortoenteric, bleeding in, 167–168, 170–172
FK506, after small intestine transplantation, 414
in pediatric patients, 728–729, 731, 735
Fluid management, in short bowel syndrome, 408
Fluoro-arabinofuranosyl-iodouracil, in hepatitis B, 595
Folate deficiency, after gastric surgery, 246
Food, hepatitis A transmission in, 439
Food dye ingestion, versus bleeding, 94
Formulas, infant, after small intestine transplantation, 735
Functional fecal retention, in pediatric patients, 627–628
Fundoplication, Nissen, results of, 219, 374–377

Gallbladder disorders, after bariatric surgery, 353–354
after gastrectomy, 209–210
after vagotomy, 209–210, 274
in parenteral nutrition, 409
Gardner's syndrome, bleeding in, 111–112
Gas bloat, after antireflux surgery, 382–384
Gastrectomy, syndromes after. See *Postgastrectomy syndromes*.
Gastric acid, secretion of, measurement of, in postgastrectomy syndromes, 190
recurrent ulcer and, 295–297, 302–305
Gastric artery, embolization of, 148–150, 155–156
Gastric atony, in Roux syndrome. See *Roux stasis (limb) syndrome*.
Gastric banding, in morbid obesity, 349
Gastric bypass, in morbid obesity, 348–350
Gastric emptying. See also *Dumping syndrome*.
after gastric surgery, nutritional aspects of, 236–239
after pyloroplasty, 204
after vagotomy, 204–206, 330–332, 334–337
development of, 659–661
in pediatric patients, 659–661
liquid vs. solid, 330
modification of, pacing in, 394–395
prokinetic agents for, 315–325
normal physiology of, 330
Gastric reflexes, for food storage, 199–201
Gastric sieving defects, after gastric surgery, 237
Gastric wrapping, in morbid obesity, 349
Gastrin, measurement of, in recurrent peptic ulcer, 300–301
Gastritis, alkaline reflux. See *Alkaline reflux gastritis*.
Helicobacter pylori in, 709–711
Gastroduodenostomy, loop syndromes after, 224–225
Gastroesophageal reflux. See *Reflux, gastroesophageal*.

Gastrogastrostomy, in morbid obesity, 348–349
Gastrointestinal motility. See *Motility*.
Gastrointestinal pacing. See *Pacing, gastrointestinal*.
Gastrojejunostomy, Billroth II. See *Billroth II procedure*.
Roux-en-Y, historical background of, 327–328
in dumping syndrome, 271–272
in recurrent peptic ulcer, 307–308
postsurgical syndromes in. See *Roux stasis (limb) syndrome*.
Gastroparesis, in Roux syndrome. See *Roux stasis (limb) syndrome*.
Gastroplasty, in morbid obesity, 348–349
Gastrostomy, in small intestine transplantation, 731
Glomerulonephritis, hepatitis C in, 433
Graft-versus-host disease, after small intestine transplantation, 738
Granulocyte-macrophage colony-stimulating factor, in hepatitis B, 758
Guaiac test, for occult bleeding, 55

Hamartomatous polyp syndromes, bleeding in, 109–111
Heartburn, postoperative, 220–223
recurrent, after antireflux surgery, 378–379
Helicobacter pylori infection, alkaline reflux gastritis and, 286
in pediatric patients, 107–108. See also under *Peptic ulcer disease, in pediatric patients*.
without peptic ulcer disease, 710–711
Hemangioma, in pediatric patients, 97–98
small intestinal, 76
Hemicolectomy, in diverticulosis, 18
in vascular ectasia, 9–10, 18
Hemobilia, in pediatric patients, 113
radiologic management of, 170, 173
Hemoccult test, 55, 60
Hemolytic-uremic syndrome, bleeding in, 104–105
in enterohemorrhagic *Escherichia coli* infection, 641–642
HemoQuant test, in occult blood detection, 57
Hemorrhage. See *Bleeding*.
Hemorrhagic colitis, enterohemorrhagic *Escherichia coli* in, 641–642
Henoch-Schönlein purpura, bleeding in, 34, 103–104
Hepatitis, autoimmune. See *Autoimmune hepatitis*.
cryptogenic, 551
in pediatric patients, 753–767
autoimmune, 764
in Epstein-Barr virus infection, 763–764
in liver transplantation, 764–765
viral, 753–763
non-A, non-B, blood-borne. See *Hepatitis C*.
water-borne. See *Hepatitis E*.
viral. See specific disease, e.g., *Hepatitis B; Viral hepatitis*.
Hepatitis A, clinical features of, 754–755
diagnosis of, historical overview of, 458
in pediatric patients, 754
molecular, 490–491
serologic, 460–463
epidemiology of, 437–441, 754
in autoimmune hepatitis, 553
in pediatric patients, 754–755
prevention of, 440–441, 755
transmission of, 438–440
treatment of, 755
vaccines for, 440–441, 755
antibodies induced by, determination of, 462–463
Hepatitis A virus, antibodies to, determination of, 459–463
vaccine-induced, 462–463
molecular biologic features of, 480–481
morphology of, 754
Hepatitis B, acute, diagnosis of, 463–464
acute nonfulminant, viral mutation in, 507–508
antigens of, determination of, 459–460
vs. viral serum titer, 442
asymptomatic, mutant virus in, 466
carriers of, diagnosis of, 464–465
family vaccination recommendations, 532
chronic, diagnosis of, 464–465
treatment of, interferon in, 574, 591–592
viral mutation in, 508–510
clinical features of, in pediatric patients, 757
diagnosis of, historical overview of, 458
in pediatric patients, 756
molecular, 486–487, 491–493
serologic, 463–467
DNA of, determination of, 491–493
epidemiology of, 441–445
familial clustering and, 528
in adopted Asian children, 529
in Asian Americans, 524–530
in immunocompromised persons, 517
in neonates, 526–528
in pediatric patients, 756
in pregnancy, in Asian Americans, 525–526
fulminant, viral mutation in, 510–511
hepatitis C association with, 494

hepatitis delta association with, 450, 493, 495
hepatocellular carcinoma and, 434, 568–570, 572
in Asian Americans, **523–536**
epidemiology of, 524–530
prevention of, 530–533
treatment of, 533–534
in autoimmune hepatitis, 552–553, 555, 557–558, 560
in HIV infection, 518
in immunocompromise, **515–521**
in pediatric patients, 756–759
natural history of, in HIV infection, 519
pathophysiology of, 431–432
prevention of, 445
in Asian Americans, 530–533
in pediatric patients, 757–758
vaccines for, 757–758
reactivated, diagnosis of, 465
transmission of, 442–445
child-to-child, 527
perinatal, 526–528
treatment of, 432, **581–601**
alternative agents in, 594–596
antiviral agents in, combinations of, 593–594
historical view of, 583–584
for hepatocellular carcinoma prevention, 574
in Asian Americans, 533–534
in pediatric patients, 757–758
interferon in, 518, 574, 584–594
dose in, 590–591
in combination therapy, 593–594
monitoring of, 590–591
nonresponders to, 596
response to, 584–589
side effects in, 589–590
liver biopsy in, 582–583
serologic endpoints in, 581–582
vaccines for, 445, 573, 758–759
in Asian Americans, 531–533
viral escape mutants and, 503–507
window period of, 464, 467
Hepatitis B virus, antibodies to, determination of, 463–467
molecular techniques in, 491
antigens of, 432
core, detection of, 463–467, 756
variants of, 511
detection of, in hepatitis delta diagnosis, 471
envelope, clearance of, in treatment, 582, 586–588
detection of, 464–465
variants of, 502–507
immune response to, 501–502
precore, variants of, 507–511
surface, clearance of, in treatment, 582, 586
detection of, 464–465, 756
DNA of, clearance of, in treatment, 582, 586–588
detection of, 489–490, 756
genomic organization of, 499–501
immune response to, 501–502
molecular biologic features of, 480–482
variants of, 432, **499–514**
asymptomatic infection in, 466
core, 511
detection of, 466, 492
envelope, 502–507
precore, 507–511
X gene, 512
Hepatitis C, acute, diagnosis of, 469–470
chronic, diagnosis of, 470
treatment of, **603–613**
alternative agents in, 610
goals of, 605
interferon in, 605–610
pathogenesis and, 604–605
clinical features of, in pediatric patients, 761
diagnosis of, 432–433
branched DNA amplification in, 489–490
historical overview of, 458
in pediatric patients, 760–761
molecular, 486, 493–495
serologic, 467–470
disorders associated with, 433–434
epidemiology of, 445–449
in immunocompromised persons, 517–518
in pediatric patients, 760
hepatitis B association with, 494
hepatocellular carcinoma and, 434, 446, 570–572
histology of, 538
histopathology of, 761
in autoimmune hepatitis, 549–561
in immunocompromise, **515–521**
in pediatric patients, 760–761
natural history of, 603–604
in HIV infection, 519
pathogenesis of, 604–605
pathophysiology of, 431–432, 516–517
prevention of, 449, 761
relapse in, treatment of, 608
transmission of, 432, 446–448
treatment of, 432, **603–613**
alternative agents in, 610
for hepatocellular carcinoma prevention, 574
goals of, 605
in pediatric patients, 761
interferon in, 605–610
pathogenesis and, 604–605
relapse in, 608
vaccines for, 573–574

Hepatitis C *(Continued)*
vs. autoimmune hepatitis, 557
Hepatitis C virus, antibodies to, determination of, 459–460, 467–470
prevalence of, 446
antigens of, detection of, 761
DNA of, detection of, 489–490
molecular biologic features of, 480–482
replication of, 604
variants of, 433
Hepatitis delta, clinical features of, 760
diagnosis of, 759–760
historical overview of, 458
molecular, 495–496
serologic, 471–472
epidemiology of, 450, 759
hepatitis B association with, 450, 493, 495
hepatocellular carcinoma and, 572–573
in pediatric patients, 759–760
prevention of, 760
treatment of, 760
Hepatitis delta virus, antibodies to, detection of, 471–472
antigen of, detection of, 471
molecular biologic features of, 480–482
Hepatitis E, **537–546**
clinical features of, 538–539, 763
diagnosis of, 540
historical overview of, 458
in pediatric patients, 762
molecular, 496
serologic, 472–473
epidemiology of, 450–451, 537–538
in pediatric patients, 761
in pediatric patients, 761–763
in pregnancy, 538
pathogenesis of, 540–541
pathology of, 539–540
prevention of, 542–543, 763
transmission of, 450–451, 538
treatment of, 763
Hepatitis E virus, antibodies to, 541
determination of, 472
antigens of, detection of, 472–473
characteristics of, 541–542
molecular biologic features of, 480–481, 483
Hepatitis F, in pediatric patients, 763
Hepatitis M/P, in pediatric patients, 763
Hepatitis non-ABCDE, epidemiology of, 437, 451
Hepatocellular carcinoma, **567–579**
alcohol in, 573
epidemiology of, 567
in Asian Americans, 530
hepatitis B in, 434, 568–570, 572
hepatitis C in, 434, 446, 570–572
hepatitis delta in, 572–573
prevention of, 573–574
risk factors for, 568
screening for, 574–575
treatment of, 575–576
Hepatocytes, abnormalities of, in hepatitis E, 539–540
Hereditary disorders. See also *Pancreatitis, hereditary.*
in pediatric patients, bleeding in, 109–112
Hernia, hiatal. See *Hiatal hernia.*
retroanastomotic, after gastroduodenostomy, 225
Herpes virus infections, hepatitis in, in pediatric patients, 764
Hiatal hernia, after antireflux surgery, 219–220, 384–385
postoperative, 222
Hill antireflux operation, results of, 373–374
Hirschsprung's disease, constipation in, 625–627, 629
embryology of, 657–658
Hirschsprung's-associated enterocolitis, 99–100
Histamine$_2$-receptor antagonists, in peptic ulcer disease, in pediatric patients, 716–719
recurrent, 301, 305–306
in short bowel syndrome, 406
HIV infection. See *Human immunodeficiency virus infection.*
Hollander test, in recurrent peptic ulcer, 302
Hookworm infection, occult bleeding in, 59
Human immunodeficiency virus infection, bleeding in, 167–169
hepatitis in, autoimmune, 553
in pediatric patients, 764
viral, 518–519
intussusception in, 39
Human leukocyte antigens, in autoimmune hepatitis, 548–549, 557–558
Hybridization techniques, in viral hepatitis diagnosis, 484–487, 492, 494–495
Hydrocortisone, after small intestine transplantation, 731
25-Hydroxyvitamin D, measurement of, in cholestasis, 684–687
Hypergastrinemia, recurrent peptic ulcer and, 300–301
Hyperlipidemia, vitamin E status evaluation in, 694, 698
Hypertension, portal. See *Portal hypertension.*
Hypocalcemia, after gastric surgery, 251–252
Hypochlorhydria, after gastric surgery, 245–246, 248

Idiopathic chronic ulcerative enteritis, 38
Ileal graft, distal onlay-reversed, in postvagotomy diarrhea, 275
Ileocolic varices, arteriography of, 137
Ileostomy, Bishop-Coop, in small intestine transplantation, 731
Immune globulin, in hepatitis A, 440
in hepatitis B, 758–759
Immunoassay, in *Helicobacter pylori* infection, 714–715
in hepatitis diagnosis, 458–460
hepatitis C, 467–470
hepatitis E, 472
Immunochemical techniques, in occult blood detection, 57
Immunocompromise, hepatitis in, in HIV infection, 518–519
prevalence of, 517–518
reactivation of, 465
Immunosuppressive therapy, after small intestine transplantation, 414, 728, 731, 735
In situ hybridization, in viral hepatitis diagnosis, 487
In situ polymerase chain reaction hybridization, in hepatitis C virus detection, 495
Incontinence, fecal, in pediatric patients. See *Encopresis*.
Incretin effect, in dumping syndrome, 264
Infants, bleeding in. See *Pediatric patients, bleeding in*.
formulas for, after small intestine transplantation, 735
gastrointestinal motility development in. See *Motility, in pediatric patients, development of*.
Infections, after bariatric surgery, 351
after small intestine transplantation, in pediatric patients, 736
bleeding in, in pediatric patients, 112
necrotizing enterocolitis in, 99
occult, 59
small intestinal, 74
diarrhea in. See *Diarrhea, infectious*.
Inflammatory bowel disease, in pediatric patients, 108–109
occult bleeding in, 59
Insulin-hypoglycemia test, for gastric secretion, in recurrent peptic ulcer, 302
for pancreatic polypeptide secretion, in dysphagia, 219
Interferon, in hepatitis B, 432, 518, 574, 584–594
dose in, 590–591
in combination therapy, 593–594
monitoring of, 590–591
response to, 584–589
side effects in, 589–590
in hepatitis C, 574, 605–610
in hepatocellular carcinoma, 575–576
Interferon alpha-2, in hepatitis B, 758
in hepatitis C, 758
Intraoperative enteroscopy, in bleeding, 83–84
Intrinsic factor deficiency, after gastric surgery, 245–246
Intussusception, bleeding in, 38–40, 102–103
in HIV infection, 39
jejunogastric, postoperative, 225
small intestinal, after bariatric surgery, 357
Iron deficiency, after bariatric surgery, 366
after gastric surgery, 245, 247–249
in occult bleeding, 57
Ischemia, colonic, 30–31
mesenteric, 27–31

Jaundice, after gastroduodenostomy, 225
in hepatitis B, 757
Jejunal graft, antiperistaltic, in postvagotomy diarrhea, 275
Jejunal interposition operation, in dumping syndrome, 271
Jejunogastric intussusception, postoperative, 225
Jejunoileal bypass, in morbid obesity, 347
complications of, 354–358
Jejunum, Dieulafoy lesion of, 33–34
diverticula of, 31–32, 74–75
ulceration of, 37–38
vascular lesions of, 75–76
Juvenile polyposis, bleeding in, 109–110

Kasai procedure, bleeding after, 138
Kidney, hepatitis C effects on, 433
Kidney stones, after bariatric surgery, 356
in short bowel syndrome, 409
Klippel-Trenaunay syndrome, bleeding in, 97
Knowledge deficit, in bariatric surgery, 352
Kupffer cells, appearance of, in hepatitis E, 539

Lactose intolerance, after gastric surgery, 231
Laminin, in enteric nervous system development, 657–658
Laser therapy, in radiation colitis, 26
Leiomyoma, small intestinal, bleeding from, 71–72

Leiomyosarcoma, small intestinal, bleeding from, 71–72
Levamisole, in hepatitis B, 593
Ligase chain reaction, in viral hepatitis diagnosis, 489–490
Liver, biopsy of, in hepatitis B, 582–583
cholestatic disease of. See *Cholestasis.*
dysfunction of, after bariatric surgery, 358
in parenteral nutrition, 409
end-stage disease of, esophageal varices in, 105
small intestine transplantation in, 729–730
hepatocellular carcinoma of. See *Hepatocellular carcinoma.*
transplantation of, in pediatric patients, hepatitis after, 764–765
with small intestine transplantation, 729–731
complications of, 736–738
postoperative management in, 731
rejection of, 731, 735–736
results of, 736
Liver membrane antigen, antibodies to, in autoimmune hepatitis, 551
Liver/kidney microsomes, antibodies to, in autoimmune hepatitis, 549–550, 556
Loop syndromes, postoperative, evaluation of, 224–225
Loperamide, in short bowel syndrome, 407
Lymphoid nodular hyperplasia, bleeding in, 102
Lymphoma, small intestinal, bleeding from, 72
Lymphoproliferative disease, after small intestine transplantation, 737–738
Lysolecithin, in alkaline reflux gastritis, 285

Malabsorption, of caloric foods, after gastric surgery, 228–241
Malabsorptive operations, for morbid obesity, complications of, 354–358
Maldigestion, after gastric surgery, 228–241
Mallory-Weiss tear, arteriography of, 145–146
in pediatric patients, 113
Malnutrition. See *Nutrition, disorders of.*
Malondialdehyde, measurement of, in vitamin E status evaluation, 698
Malrotation, intestinal, bleeding in, 95
Manometry, anorectal, in defecation disorders, in pediatric patients, 630
antroduodenal, in preterm infants, feeding readiness and, 665–666
colonic, in pediatric patients, 631
Marathon running, gastrointestinal bleeding in, 40–41
Matrix dot blot immunoassay, for hepatitis C, 468–469
Measles, autoimmune hepatitis and, 554
hepatitis M/P in, in pediatric patients, 763
Meckel's diverticulum, bleeding in, 32–33, 73
in pediatric patients, 96–97
Meckel's scan, in bleeding evaluation, 78
Menadiones. See *Vitamin K.*
Menaquinones. See *Vitamin K.*
Mesenteric vascular insufficiency, 27–31
Metabolic complications, of bariatric surgery, 355–356
Metastasis, to small intestine, bleeding from, 72
Methyl prednisolone, in small intestine transplantation, 731, 735
Metoclopramide, in alkaline reflux gastritis, 289
in gastric emptying, in pediatric patients, 661
in postgastrectomy syndromes, 316, 338
Metronidazole, in peptic ulcer disease, in pediatric patients, 719–720
Migrating motor complex, development of, 661–664
in Roux limb, 332–334, 336–337
vagotomy effects on, 206–209
Milk protein intolerance, bleeding in, 100–101
Mineral deficiencies, after bariatric surgery, 366
Mineral oil, for defecation disorders, in pediatric patients, 633
Molecular diagnosis, for viral hepatitis, 479–498
advantages of, 490
hepatitis A, 490–491
hepatitis B, 491–493
hepatitis C, 493–495
hepatitis D, 495–496
hepatitis E, 496
principles of, 483–490
virus features and, 480–483
Molecular hybridization, in viral hepatitis diagnosis, 484–487, 492, 494–495
Morbid obesity, bariatric surgery in. See *Bariatric surgery.*
Motility. See also *Pacing, gastrointestinal.*
antroduodenal, in pediatric patients, development of, 661–666
colonic, in pediatric patients, development of, 666–667
gastric, after gastrectomy, 197
after vagotomy, 197, 199–204
in pediatric patients, development of, 659–661

overview of, 197–204
in pediatric patients, development of, **655–671**
antroduodenal, 661–666
colonic, 666–667
enteric nervous system, 656–658
esophageal, 659
gastric emptying, 659–661
smooth muscle, 656
sucking and swallowing, 658–659
small intestinal, after transplantation, 736–737
regulation of, after resection, 412–413
segmental reversal and, 413
Multivisceral transplantation, in pediatric patients, 731
Munchausen's syndrome by proxy, apparent bleeding and, 94
Mutation, of hepatitis viruses. See specific virus, *variants of.*
Myoelectric studies, in Roux syndrome, 332–337

Needlestick injury, hepatitis C transmission in, 447
Neonatal necrotizing enterocolitis, 98–99
Neonates, hepatitis B in, 443, 526–528
hepatitis C in, 448
Nephrolithiasis, in short bowel syndrome, 409–410
Nervous system, enteric, development of, 656–658
Nested polymerase chain reaction, in viral hepatitis diagnosis, 487
Neurologic assessment, in vitamin E status evaluation, 698–699
Neurologic disease, after bariatric surgery, 366
after gastric surgery, 254
Neurotensin, in dumping syndrome, 263
Nissen fundoplication, results of, 219, 374–377
Nitroimidazoles, in peptic ulcer disease, in pediatric patients, 719
Nonocclusive mesenteric ischemia, 30
Nonsteroidal anti-inflammatory drugs, occult bleeding from, 58–59
Northern blot, in viral hepatitis diagnosis, 485, 492
Nuclear scan, in bleeding evaluation, small intestinal, 78
Nucleoside analogues, in hepatitis B, 595–596
Nutrients, absorption of, in short bowel syndrome, strategies for, 405–408
deficiencies of, in short bowel syndrome, 408–409
Nutrition, after small intestine transplantation, 735

disorders of, after gastric surgery, **227–260**
anemia, 245–249
azotorrhea, 229
bacterial overgrowth syndrome, 253–254
bone disease, 249–253
caloric food maldigestion and malabsorption, 228–241
carbohydrate malabsorption, 229, 231
for morbid obesity, 355–356, 365–366
from concurrent disease unmasking, 254
gastric emptying alterations, 236–239
gastric sieving defects, 237–238
iron deficiency, 245, 247–249
pancreatic insufficiency, 231, 236, 239
satiety, 243–245
steatorrhea, 228–229, 237–238
treatment of, 254–255
underweight, 241–243
maintenance of, in short bowel syndrome, 404–405

Obesity, bariatric surgery in. See *Bariatric surgery.*
classification of, 346
Obstruction, colonic, after bariatric surgery, 351, 358
in bariatric surgery, 351
pyloric, in recurrent peptic ulcer, 297
small intestinal, after bariatric surgery, 357
after resection, 410–411
Occult bleeding, **53–66**
causes of, 58–59
detection of, 54–57
in colorectal cancer screening, 59–62
evaluation of, 62–63
iron deficiency in, 57
physiologic, 54
in pediatric patients, 94
Octreotide, in dumping syndrome, 267–269
in hereditary pancreatitis, 748
in peptic ulcer disease, in pediatric patients, 715
in short bowel syndrome, 407
OKT3 monoclonal antibodies, in small intestine transplantation, 735
Omeprazole, gastrin measurement and, 301
in peptic ulcer disease, in pediatric patients, 720

Omeprazole *(Continued)*
recurrent, 306
Osler-Weber-Rendu syndrome, bleeding in, 76, 87–88, 98
Osteomalacia, after gastric surgery, 249–253
Oxalate urinary stones, after bariatric surgery, 356

Pacemaker, in gastrointestinal motility, 392–393
Pacing, gastrointestinal, **391–402**
after cholecystectomy, 399–400
after Roux-en-Y procedure, 333–334
after vagotomy, 201–203
in canine models, 393–399
in dumping syndrome, 396–399
in gastroparesis, 399
in health, 392–393
in Roux stasis syndrome, 398
in short bowel syndrome, 395–396
in tachygastria, 398–399
Pain, after bariatric surgery, 364
in defecation disorders, 628
in hereditary pancreatitis, 743–744
in recurrent peptic ulcer, 297
in Roux syndrome, 329
postoperative, 220–223
Pancreas, calcification of, 745, 747
insufficiency of, after gastric surgery, 231, 236, 239
pseudocyst of, after gastroduodenostomy, 225
Pancreatic duct, sphincteroplasty of, in hereditary pancreatitis, 749
Pancreatic enzymes, oral supplementation with, in hereditary pancreatitis, 748
Pancreatic polypeptide, secretion of, after vagotomy, 219
Pancreaticoduodenal arcade, embolization of, 154
Pancreaticojejunostomy, in hereditary pancreatitis, 749
Pancreatitis, after gastroduodenostomy, 225
hereditary, **743–752**
clinical factors in, 743–745
diagnosis of, 745
differential diagnosis of, 747–748
natural history of, 744–745
pathogenesis of, 746–747
treatment of, 748–749
variants of, 747
Papillotomy, in hereditary pancreatitis, 749
Paraesophageal hernia, after antireflux surgery, 219–220, 384–385
postoperative, 222
Parenteral nutrition, in small intestinal disease, as transplantation criteria, 729–730
liver dysfunction in, 409
Patient education, on bariatric surgery, 352
Payne bypass, in morbid obesity, 347
Peak acid output test, in recurrent peptic ulcer, 303
Pediatric patients, bleeding in. See under *Bleeding*.
cholestatic liver disease in, fat-soluble vitamins and, **673–705**
constipation in, management of, **621–636**
encopresis in, management of, **621–636**
gastrointestinal motility in, development of, **655–671**
hepatitis in, **753–767**
autoimmune, 764
in Epstein-Barr virus infection, 763–764
in liver transplantation, 764–765
infectious diarrhea in, **637–654**
liver transplantation in, with small intestine transplantation, complications of, 736–738
postoperative management in, 731
rejection of, 731, 735–736
results of, 736
multivisceral transplantation in, 731
pancreatitis in, hereditary, **743–752**
peptic ulcer disease in, **707–725**
small intestine transplantation in, **727–742**
Pentane gas, expired, measurement of, in vitamin E status evaluation, 698
Peptic ulcer disease, after bariatric surgery, 362–363
bleeding in, in pediatric patients, 106–107
occult, 58
vasopressin therapy in, 152–153
in pediatric patients, **707–725**
diagnosis of, 711–715
epidemiology of, 707, 711
Helicobacter pylori in, 708–711
biopsy in, 713
breath tests in, 713–714
culture of, 713
diagnosis of, 711–715
endoscopic appearance of, 712
serologic tests in, 714–715
spectrum of, 709–711
treatment of, 716–720
urease tests in, 713
primary, 708
spectrum of, 709–711
treatment of, acute, 715–716
antibacterial, 718–720
long-term, 716–717
maintenance, 717–718
preventive, 717
in short bowel syndrome, 409
postoperative recurrent, **295–311**

causes of, 298–299
clinical presentation of, 297–298
evaluation of, 298–305
incidence of, 295–297
risk factors for, 295–297
treatment of, 305–308
Peristalsis, pacing of. See *Pacing, gastrointestinal.*
Pernicious anemia, after gastric surgery, 245–246
Peutz-Jeghers syndrome, bleeding in, 110–111
Phlebectasia, small intestinal, 75–76
Phylloquinones. See *Vitamin K.*
PIVKA (protein in vitamin K absence) assay, in vitamin K status evaluation, 690
Plaque-reducing assay, for hepatitis A antibody, 462
Pneumatosis cystoides intestinalis, after bariatric surgery, 358
Polyarteritis nodosa, bleeding in, 34
viral hepatitis in, 433
Polyethylene glycol-electrolyte solution, for defecation disorders, in pediatric patients, 633
Polymerase chain reaction, in viral hepatitis diagnosis, 487, 489
hepatitis B, 492
hepatitis C, 469, 493–495
hepatitis delta, 496
hepatitis E, 496
Polyposis, in pediatric patients, bleeding in, 109–112
Polypropylene mesh, in bariatric surgery, complications with, 364–365
Porphyria cutanea tarda, hepatitis C in, 433–434
Portal colopathy, 25
Portal hypertension, bleeding in, colonic, 25
in pediatric patients, 105
occult, 59
radiologic management of, 160, 162–163, 166–167
Portal vein, phlebitis of, in hepatitis E, 539
Portosystemic shunt, in variceal bleeding, colonic, 25
transjugular intrahepatic, 163, 166–167
Postgastrectomy syndromes, **193–213**, **215–226**
abdominal pain, evaluation of, 220–223
alkaline reflux gastritis, 191, **281–294**
anemia, 245–249
azotorrhea, 229
bacterial overgrowth syndrome, 253–254
bone disease, 249–253
caloric food maldigestion and malabsorption, 228–241
carbohydrate malabsorption, 229, 231
clinical features of, 313–315
dumping syndrome. See *Dumping syndrome.*
dysphagia, evaluation of, 216–220
enterogastric reflux, 197
evaluation of, 189–192
from concurrent disease unmasking, 254
gallbladder motility disorders, 209–210
gastric emptying abnormalities, 204–205, 236–239
gastric sieving defects, 237–239
heartburn, evaluation of, 220–223
interdigestive motility abnormalities, 206–209
iron deficiency, 245, 247–249
loop syndromes, 224–225
neurologic disease, 254
nutritional disorders. See *Nutrition, disorders of.*
pancreatic insufficiency, 231, 236, 239
pathophysiology of, 313–315
postprandial discomfort, evaluation of, 223–225
prokinetic agents in, **313–325**, 337–338
reflux, evaluation of, 222–223
Roux. See *Roux stasis (limb) syndrome.*
satiety, 243–245
steatorrhea, 228–229, 237–238
underweight, 241–243
vomiting, evaluation of, 223–225
Postprandial discomfort, postoperative, evaluation of, 223–225
Postsurgical syndromes, after antireflux surgery, **371–389**
after bariatric surgery, 244–245, **345–369**
after gastrectomy. See *Postgastrectomy syndromes.*
after vagotomy, **193–213**
alkaline reflux gastritis, **281–294**
cardiac, 351
diarrhea, **272–276**
dumping. See *Dumping syndrome.*
evaluation of, **189–192**
gastric atony, **327–343**
infections, 351
intestinal pacing in, **391–402**
nutritional disorders, **227–260**
peptic ulcer recurrence, **295–311**
respiratory, 351
Roux syndrome, **327–343**
short bowel syndrome, **403–420**
Post-transplant lymphoproliferative disease, after small intestine transplantation, 737–738
Pregnancy, hepatitis B in, in Asian Americans, 525–526
hepatitis E in, 538
Proctitis, radiation-induced, 26
Proctography, evacuation, in pediatric patients, 630

Prokinetic agents, in postgastrectomy syndromes, **313–325**, 337–338
bethanechol, 315–316, 338
cisapride, 316, 318–320, 338
domperidone, 320, 338
erythromycin, 320–322, 335, 338
metoclopramide, 316, 338
Prostaglandin E, after small intestine transplantation, 731
in peptic ulcer disease, in pediatric patients, 716
Prosthesis, Angelchik, in reflux management, 377–378
for bariatric surgery, complications with, 364–365
Protein in vitamin K absence assay, in vitamin K status evaluation, 690
Protein-calorie malnutrition, after bariatric surgery, 365
Prothrombin time, in vitamin K status evaluation, 690–691
Pseudocyst, pancreatic, after gastroduodenostomy, 225
Pseudo-Zollinger-Ellison syndrome, recurrent peptic ulcer and, 300–301
Psychosocial influences, on bariatric surgery, 352
Puestow procedure, modified, in hereditary pancreatitis, 749
Push enteroscopy, in bleeding, 81–83
Pyloroplasty, gastric emptying after, 204–205, 330
in dumping syndrome, 270
with vagotomy, 196
Pylorus, function of, vagotomy effects on, 203–204
obstruction of, in recurrent peptic ulcer, 297

Radiation injury, enterocolitis in, 25–26, 74
in pediatric patients, 113
Radioimmunoassay, in hepatitis diagnosis, 458
Radioimmunofocus inhibition test, for hepatitis A antibody, 462
Radiology, in bleeding management, **123–181**
algorithms for, 158–159
barium studies, 124–125
in aortoenteric fistula, 167–168, 170
in Dieulafoy lesion, 174
in hemobilia, 170, 173
in HIV infection, 167
in portal hypertension, 160, 162–163, 166–167
radionuclide scans, 125–128
visceral arteriography in, 128–160
advantages of, 129
therapy with, 139–160
timing of, 129, 131
in hereditary pancreatitis, 745
Radionuclide scans, in bleeding evaluation, 125–128
Ranitidine, in peptic ulcer disease, in pediatric patients, 107
Receptive relaxation reflex, gastric, 199–201
Recombinant immunoblot assay, for hepatitis C, 468
Rectal compliance testing, in pediatric patients, 631
Rectopexy, in solitary rectal ulcer syndrome, 23–24
Rectum, bleeding in, from solitary rectal ulcer syndrome, 21–24
in endometriosis, 41–43
defecation physiology and, 622–623
Reflexes, gastric, for food storage, 199–201
Reflux, alkaline, gastritis in. See *Alkaline reflux gastritis.*
gastroesophageal, after antireflux surgery, 378–379
after bariatric surgery, 363
after gastric cancer surgery, 221–222
after vagotomy, 197
bleeding in, 101–102
postoperative, evaluation of, 222–223
surgical treatment of. See *Antireflux surgery.*
Rejection, in small intestine transplantation, 737
monitoring of, 731–735
treatment of, 735
Relative dose response test, for vitamin A status, 678, 680–681
Respiratory complications, of bariatric surgery, 351
Retained antrum syndrome, gastrin levels in, 300–301
Retinoids. See *Vitamin A.*
Retinol:retinol-binding protein molar ratio, in vitamin A status evaluation, 678–679
Retroanastomotic hernia, after gastroduodenostomy, 225
Reverse transcription polymerase chain reaction, in viral hepatitis diagnosis, 489
Rheumatoid arthritis, bleeding in, 35
Ribavirin, in hepatitis B, 595
in hepatitis C, 610
Rotavirus infections, in pediatric patients, 645–647
Roux stasis (limb) syndrome, **327–343**
after alkaline reflux gastritis corrective surgery, 290–292
clinical picture of, 329
complications of, 291–292

etiology of, 330–334
gastric emptying studies in, 331–332
historical aspects of, 327–328
myoelectric recording studies in, 332–337
physiology of, 329–330
treatment of, medical, 337–338
pacing in, 398
surgical, 338–340
vagotomy and, 334–337
Roux-en-Y gastrojejunostomy, in dumping syndrome, 271–272
in recurrent peptic ulcer, 307–308
postsurgical syndromes in. See *Roux stasis (limb) syndrome.*
Running, marathon, gastrointestinal bleeding in, 40–41

Saccharomyces boulardii, in clostridial diarrhea therapy, 640
Scintigraphy, in alkaline reflux gastritis, 288
in bleeding evaluation, 16–17
small intestinal, 85–87
in recurrent peptic ulcer, 301
Sclerotherapy, in variceal bleeding, 162
Serologic diagnosis, of *Helicobacter pylori* infection, in pediatric patients, 714–715
of viral hepatitis, **457–477**
hepatitis A, 460–463
hepatitis B, 463–467
hepatitis C, 467–470
hepatitis D, 471–472
hepatitis E, 472–473
historical overview of, 458
principles of, 458–469
Sexual activity, viral transmission in, hepatitis B, 443–445
hepatitis C, 447
hepatitis delta, 450
Sham feeding test, in recurrent peptic ulcer, 302–303
Shigella infection, in pediatric patients, 648–649
Short bowel syndrome, **403–420**
causes of, 403–404
clinical features of, 403–404
management of, absorption maximization in, 405–408
complication prevention in, 408–410
early, 404
goals of, 404–410
intestinal transplantation in, 414–415
nutritional maintenance in, 404–405
pacing in, 395–396
surgical, 410–415
pathophysiology of, 404
Sieving, gastric, defects of, after gastric surgery, 237–238
Sigmoidoscopy, in occult bleeding, 63
in solitary rectal ulcer syndrome, 22
with enterotomy, 85
Sigstad clinical dumping score, 265
Sliding hernia, recurrent, after antireflux surgery, 384–385
Slipped Nissen fundoplication, 375–376
Slot blot hybridization, in viral hepatitis diagnosis, 485–486, 494–495
Small bowel series, in bleeding evaluation, 76–77
Small intestine, absorption in, postoperative, 209
bleeding in, **67–91**
causes of, 68–76
embolization therapy in, 147, 151–153
evaluation of, 76–86
in aortoenteric fistula, 167–168, 170
in congenital malrotation, 95
in Dieulafoy lesion, 33–34
in diverticulosis, 31–32, 74–75
in endometriosis, 41–43
in Gardner's syndrome, 111–112
in hemolytic-uremic syndrome, 104–105
in Henoch-Schönlein purpura, 34, 103–104
in Hirschsprung's-associated enterocolitis, 99–100
in infections, 112
in inflammatory bowel disease, 108–109
in intestinal duplication, 95–96
in intussusception, 38–40, 102–103
in lymphoid nodular hyperplasia, 102
in Meckel's diverticulum, 32–33, 73, 96–97
in mesenteric vascular insufficiency, 27–30
in necrotizing enterocolitis, 98–99
in peptic ulcer disease, 106–108
in ulceration, 36–38
in vascular lesions, 75–76
in vascular malformation, 97–98
in vasculitis, 34–36
radiologic management of. See *Radiology, in bleeding management.*
treatment of, 85–87
vasopressin therapy in, 143
dilations in, after resection, 411–412
intussusception of, after bariatric surgery, 357
motility of, regulation of. See also *Pacing, gastrointestinal.*
after resection, 412–413
obstruction of, after bariatric surgery, 357
after resection, 410–411

Small intestine *(Continued)*
pacemaker of, 393
preservation of, to prevent short bowel syndrome, 410
resection of, short bowel syndrome in. See *Short bowel syndrome.*
segmental reversal of, in motility control, 413
transplantation of, after resection, 414–415
in pediatric patients, **727–742**
complications of, 736–738
costs of, 738
future prospects for, 739–740
historical aspects of, 727–729
indications for, 729–730
infection prophylaxis and treatment in, 736
nutritional support in, 735
postoperative management in, 731
psychosocial impact of, 738–739
rejection in, 731–735, 737
results of, 736
selection criteria for, 729–730
technical aspects of, 730–731
Smooth muscle, antibodies to, in autoimmune hepatitis, 548, 551, 556
development of, 656
Solitary rectal ulcer syndrome, 21–24
Soluble liver antigen, antibodies to, in autoimmune hepatitis, 551
Somatostatin, in hereditary pancreatitis, 748
in short bowel syndrome, 407
Sonde enteroscopy, in bleeding, 81–84
Southern blot, in viral hepatitis diagnosis, 485, 487
Spindle cell disease, post-transplant, after small intestine transplantation, 738
Stapling operations, stomach, in morbid obesity, 348–349
Steatorrhea, after gastric surgery, 228–229, 237–238
Steatosis, hepatic, after bariatric surgery, 358
Stomach. See also *Gastric.*
accommodation response in, 200–201
capacity of, 199–200
motility of, development of, 659–661
gastrectomy effects on, 197
in pediatric patients, 659–661
overview of, 197–204
regulation of. See *Pacing, gastrointestinal.*
vagotomy effects on, 197, 199–204
pacemaker of, 392–393
stapling operations for, in morbid obesity, 348–349
Stones, gallbladder. See *Cholelithiasis.*
kidney, in short bowel syndrome, 409
pancreatic, in hereditary pancreatitis, 747
urinary, after bariatric surgery, 356
Sucking, development of, 658–659
Sucralfate, in alkaline reflux gastritis, 289
Surgery, exploratory, in small intestinal bleeding, 80
syndromes developing after. See *Postsurgical syndromes.*
Swallowing, development of, 658–659
Systemic lupus erythematosus, bleeding in, 35

Tachygastria, treatment of, pacing in, 398–399
Technetium-99m scan, in bleeding evaluation, 125–128
small intestinal, 78
Telangiectasia, small intestinal, 76
Tetracycline, in peptic ulcer disease, in pediatric patients, 719
Thrombosis, of mesenteric arteries, 28
of mesenteric veins, 28–29
Thymic extract, in hepatitis C, 610
Thymosin, in hepatitis B, 594–595
Thyroglobulin antibody, in autoimmune hepatitis, 556
Tocopherols. See *Vitamin E.*
Transfusions, hepatitis C transmission in, 447, 449
Transjugular intrahepatic portosystemic stent shunt, in variceal bleeding, 163, 166–167
Transplantation, multivisceral, in pediatric patients, 731
of liver. See *Liver, transplantation of.*
of small intestine. See under *Small intestine.*
Trauma, bleeding in, arteriography in, 135
Tumors. See also *Colorectal cancer.*
small intestinal, bleeding from, 71–72
Turner's syndrome, small intestinal bleeding in, 76

Ulcer(s), aphthous, in small intestine graft rejection, 732–733
in solitary rectal ulcer syndrome, 21–24
of small intestine, 36–38, 72–73
peptic. See *Peptic ulcer disease.*
Ulcerative colitis, in pediatric patients, 108–109
Ulcerative jejunitis, 37–38
Ultrasonography, in hereditary pancreatitis, 745
in small intestinal bleeding, 85
Underweight condition, after gastric surgery, 241–243

Urease tests, in peptic ulcer disease, in pediatric patients, 713
Urinary stones, in short bowel syndrome, 409
oxalate, after bariatric surgery, 356
Ursodeoxycholic acid, in alkaline reflux gastritis, 289–290

Vaccines, for cholera, 643–645
for enterotoxigenic *Escherichia coli* infection, 647–648
for hepatitis A, 440–441, 755
antibodies induced by, determination of, 462–463
for hepatitis B, 445, 573, 757–758
in Asian Americans, 531–533
viral escape mutants and, 503–507
for hepatitis C, 573–574
for rotavirus, 645–647
for viral hepatitis, 434–435
Vagotomy, **193–213**
anatomic considerations in, 194
complications of, bone disease, 253
diarrhea, 272–275
dumping syndrome, 265
dysphagia, evaluation of, 217–219
gastric emptying alterations, 236–237, 330–332, 334–337
hypergastrinemia, 300–301
pancreatic dysfunction, 236
peptic ulcer recurrence, 296–297
steatorrhea, 228–229
weight loss, 242
physiologic consequences of, on esophagogastric junction function, 197
on gallbladder function, 209–210
on gastric emptying, 204–206
on gastric motility, 199–204
on interdigestive motility patterns, 206–209
on small intestinal function, 209
repeated, in recurrent peptic ulcer, 306–307
results of, 313–315
evaluation of, 190–191
Roux syndrome and, 334–337
technique for, 194–197
Vagus nerves, anatomy of, 194
Varicella zoster virus infection, hepatitis in, in pediatric patients, 764
Varices, colonic, 24–25
arteriography of, 137
esophageal, arteriography of, 138
in pediatric patients, 105
radiologic management of, 160, 162–163, 166–167
ileocolic, arteriography of, 137
Vascular ectasia, **1–20**
colonic, 2–10
clinical features of, 6–7
epidemiology of, 6
evaluation of, 7–9, 16–17
histopathology of, 2–5
pathophysiology of, 5
treatment of, 9–10, 17–18
small intestinal, 68–71, 75–76
Vascular insufficiency, mesenteric, 27–31
Vascular malformations, bleeding in, arteriography of, 136
in pediatric patients, 97–98
occult, 59
Vasculitis, bleeding in, 34–36, 103–104
small intestinal, 74
Vasoconstrictors, in diverticula, 15
Vasopressin, in bleeding therapy, 139–143, 145–146, 151
in colonic varices, 25
in Dieulafoy lesion, 174
in diverticulosis, 17–18
in HIV infection, 160, 162
in portal hypertension, 160, 162
in vascular ectasia, 9
in peptic ulcer disease, in pediatric patients, 715
Venous thrombosis, mesenteric, 28–29
Vibrio cholerae infection, in pediatric patients, 638–639, 643–645
Viral hepatitis. See also specific disease, e.g., *Hepatitis B.*
autoimmune hepatitis and. See *Autoimmune hepatitis.*
chronic, pathophysiology of, 431–432
diagnosis of, 432–433, 458, 540
molecular, **479–498**
serologic, **457–477**
disorders associated with, 433–434
epidemiology of, **437–455**
hepatitis A, 437–441
hepatitis B, 441–445, **523–536**
hepatitis C, 445–449
hepatitis delta, 450
hepatitis E, 450–451, 537–538
in Asian Americans, **523–536**
in immunocompromise, 517–518
non-ABCDE, 437, 451
hepatocellular carcinoma and, 434, 446, **567–579**
historical perspective of, 429–431
in HIV infection, 518–519
in immunocompromise, **515–521**
in pediatric patients, 753–763
pathophysiology of, in immunocompromise, 516–517
recent research progress in, **429–435**
treatment of, 432
hepatitis B. See under *Hepatitis B.*
hepatitis C, 432, 574, **603–613**
vaccines for. See specific disease, e.g., *Hepatitis B.*

Viral hepatitis *(Continued)*
vs. autoimmune hepatitis, 560–561
Visceral arteriography, in bleeding management, 128–160
advantages of, 129
therapy with, 139–160
timing of, 129, 131
Visick classification, of dumping syndrome, 265
Vitamin(s), deficiencies of, after bariatric surgery, 366
in cholestasis, in pediatric patients, 673–705
Vitamin A, 674–682
biochemistry of, 674–677
deficiency of, 667–682
dietary sources of, 674–675
hepatotoxicity of, 681–682
in cholestasis, deficiency of, detection of, 667–682
metabolism of, 677
status evaluation of, 677–682
supplementation with, 682
metabolism of, 674–677
Vitamin B_{12} deficiency, after bariatric surgery, 366
after gastric surgery, 245–246
Vitamin D, 682–689
biochemistry of, 682–684, 689–690
deficiency of, 684
in cholestasis, deficiency of, 684
metabolism of, 683–684
status evaluation of, 684–687
supplementation with, 687–689
metabolism of, 682–684, 689–690
physiology of, 682–684, 689–690
Vitamin E, 691–702
biochemistry of, 691–694
in cholestasis, deficiency of, 694
metabolism of, 694
status evaluation of, 694–700
supplementation with, 700–702
metabolism of, 691–694
physiology of, 691–694
toxicity of, 702
Vitamin K, in cholestasis, status evaluation of, 690–691
supplementation with, 691
Vomiting, after bariatric surgery, 359–362
in Roux syndrome, 329
inability to, after antireflux surgery, 382–384
postoperative, evaluation of, 223–225

Wasting syndrome, in small intestine graft rejection, 733–734
Wegener's granulomatosis, bleeding in, 34–35
Weight loss, after gastric surgery, 241–243
bariatric surgery for. See *Bariatric surgery.*
inadequate, after bariatric surgery, 353, 366–367
Whipple procedure, recurrent peptic ulcer after, 308
Wrapping, gastric, in morbid obesity, 349

X gene, of hepatitis B, variants of, 512

Zidovudine, in hepatitis C, 610
Zollinger-Ellison syndrome, bleeding in, 73
recurrent peptic ulcer in, 300–301
treatment of, 307